1 Indiana University School of Medicine, Indianapolis, IN, 2 Statistical and Data Analysis Center/Harvard School of Public Health and 3 Harvard University, Boston, MA, USA
Correspondence and offprint requests to: Samir K. Gupta, MD, Division of Infectious Diseases, Indiana University School of Medicine, Wishard Hospital, OPW-430, 1001 W. 10th Street, Indianapolis, IN 46202, USA. Email: sgupta1{at}iupui.edu
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Methods. We evaluated the effects of HAART on albumin to creatinine ratios (ACRs) during the initial 64 weeks of therapy in 68 previously untreated HIV-infected subjects, without pre-existing diagnosed diabetes or hypertension, enrolled in a randomized trial comparing PI-based (n = 32) with non-PI-based (n = 36) HAART regimens. We also estimated the prevalence of albuminuria, defined as an ACR 3.4 mg/mmol, in these subjects prior to initiation of HAART.
Results. The changes in ACR over the initial 64 weeks of therapy in those receiving PIs [0.0 mg/mmol (0.4, 0.3)] and in those not receiving PIs [0.0 mg/mmol (0.5, 0.3)] were not significantly different. There was also no significant difference in the change in the ACR in the group as a whole. However, albuminuria at baseline was found in seven (10%) subjects. Five of these seven subjects had substantial improvements in ACR, ranging from 45 to 95%, with HAART use; three subjects had resolution of albuminuria. ACR at baseline significantly correlated with the baseline HIV-1 RNA level (r = 0.25; P = 0.04) and negatively with CD4 cell count (r = 0.25; P = 0.04).
Conclusion. Albuminuria in HIV-infected, treatment-naïve patients was found more frequently than expected and may be influenced by baseline immune status. Although we did not observe an effect of HAART on ACR during the first 64 weeks of therapy, we cannot exclude the possibility that HAART may be beneficial in those patients with significant albuminuria prior to treatment. Research in larger cohorts is required to investigate more definitively the associations between immune status, antiretroviral therapies and renal function in HIV-infected patients.
Keywords: albuminuria; antiretroviral therapy; cardiovascular disease; cardiovascular risk; HIV; protease inhibitors
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The link between renal and cardiovascular disorders is increasingly thought to be due to systemic endothelial dysfunction [3]. Patients receiving protease inhibitor (PI)-based regimens, as opposed to non-PI-based regimens such as those incorporating non-nucleoside reverse transcriptase inhibitors (NNRTIs), may be especially at risk for cardiovascular events [4], perhaps as a result of the association between PI and endothelial dysfunction [5]. PIs, more than NNRTIs, have also been associated with the development of the metabolic syndrome [6], which is a risk factor for vascular disease in the general population and is also associated with albuminuria [7]. Therefore, it is possible that PIs may preferentially induce albuminuria.
Alternatively, HIV can infect and disrupt the glomerular epithelium with the ensuing development of HIV-associated nephropathy (HIVAN), which may be reversed with the use of HAART [8]. Therefore, it is also possible that antiretroviral therapy, regardless of its components, may actually reduce albuminuria. In order to test these competing hypotheses, we performed a post hoc, secondary analysis of a randomized clinical trial comparing nelfinavir, a PI, with efavirenz, an NNRTI.
![]() |
Subjects and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Secondary objectives included comparing the effects of the pooled nucleoside backbone combinations (arms A and B combined vs arms C and D combined) and the four individual treatment arms on the change in albuminuria; within-group changes were also estimated. We also estimated the prevalence of albuminuria at baseline and factors associated with the baseline albumin to creatine ratio (ACR).
Prior to enrolment, all subjects who participated in both ACTG 384 and the metabolic substudy provided written, informed consent. The human research ethics committees of each participating institution approved these studies.
Study population
To be eligible for ACTG 384 and its metabolic substudy, all subjects at entry were required to be antiretroviral treatment-naïve (<7 days of previous antiretroviral use), age >13 years, have a serum creatinine <1.5 times the upper limit of normal at their institution's laboratory, and not have a diagnosis of diabetes mellitus. Subjects were not eligible if they had unexplained fever or diarrhoea within 30 days of entry or were undergoing acute therapy for a serious infection or other serious medical illness.
Laboratory methods and definitions
All urine specimens were analysed in batch for urine albumin and creatinine at a central laboratory (Quest Diagnostics, Inc., Baltimore, MD). Urine albumin was measured using an immunoturbimetric assay [coefficient of variation (CV) <5%; Kamiya Biomedical Co., Seattle, WA], and urine creatinine was measured using a modified Jaffe reaction (CV <3%; Olympus America Inc., Melville, NY). Random urine ACRs were then calculated for each sample. An ACR 3.4 mg/mmol and <34 mg/mmol (30299 mg/g) defined microalbuminuria; macroalbuminuria was defined as
34 mg/mmol (300 mg/g). These gender-neutral cut-offs were used to allow baseline (week 0) comparisons with the general US population [11]. Insulin resistance was estimated using the homeostasis model assessment-insulin resistance (HOMA-IR) [12]. The glomerular filtration rate (GFR) was estimated using the simplified MDRD equation [13]. This equation was chosen to allow staging of this cohort's baseline renal function, to allow general comparisons with other reference populations (e.g. the NHANES III cohort) and because the racial and gender demographics of this study's population are more similar to the MDRD study population than that used to derive the CockcroftGault equation; however, we acknowledge that wasting conditions such as untreated HIV infection may skew MDRD GFR estimates and, therefore, may not be as accurate.
Statistical analyses
Intent-to-treat analyses were performed for the overall group. On-treatment analyses were also completed for those who did not switch treatment arms within the first 64 weeks of the study. Unless otherwise specified, all values are presented as medians and interquartile ranges. To compare variables between treatment groups and those with and without baseline albuminuria, the Wilcoxon rank-sum test (a non-parametric version of a standard t-test) was used to compare continuous variables between groups, and Fisher's exact test was used for comparison between groups of binary variables. The Wilcoxon signed-rank test was used for assessing within-group changes in ACR between week 0 and week 64. Spearman rank correlation was used to assess the association of week 0 ACR with other variables. Mixed-models analysis of variance was used for longitudinal modelling incorporating all observations from week 0 through week 64 and for assessing the impact of various potential confounders on change over time. All P-values were two-sided and considered statistically significant if <0.05.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Endothelial dysfunction has been shown to predict the development of cardiovascular disease [15]. PI-based regimens have also been linked with endothelial dysfunction [5], and albuminuria has been associated with endothelial dysfunction in some populations [3]. Contrary to our hypothesis that albuminuria may increase during PI use, we did not find that HAART increased the ACR among treatment-naïve patients during the first 64 weeks of antiretroviral therapy; nor were there differences between the pooled or individual treatment groups. It is possible that the relationship between PI use and endothelial dysfunction may be agent specific, rather than class specific. Previous studies associating PI use with endothelial dysfunction have suggested that the pro-atherogenic lipid profile seen with protease inhibitors is the underlying cause of endothelial dysfunction [5]; however, these investigations have involved primarily indinavir. In fact, nelfinavir, when compared with other PIs, such as indinavir and ritonavir-boosted combinations, may be less likely to cause low levels of high density lipoprotein-cholesterol (HDL-C) [16]. Furthermore, triglycerides appear to improve when patients switch their PI from indinavir or saquinavir plus ritonavir to nelfinavir [17]. Therefore, the results from this study may not necessarily extend to patients receiving other PI-containing regimens. Another potential explanation for the negative results of this study may lie in the fact that the risk of cardiovascular disease among HIV patients may only increase after several years of therapy [1]; therefore, it is also possible that the relatively small sample size and duration of follow-up in this study may have precluded from finding a positive association between use of antiretrovirals and albuminuria.
We also did not see an overall improvement in ACR with the use of HAART in this small study with few subjects with substantial albuminuria. It should be noted that the use of antihypertensive medications by four subjects may have precluded finding a more definitive improvement in ACR with the use of HAART. However, we did find that five of the seven subjects with baseline albuminuria had substantial improvements of 4595% with HAART over the initial 64 weeks. This suggests that albuminuria in HIV-infected patients may initially be the result of direct renal damage by HIV that may improve with HAART [8]. Alternatively, albuminuria may indeed be related to endothelial dysfunction caused by HIV infection that, at least in the short-term, seems to improve from HAART use [18].
We found in this cohort a higher prevalence than expected of albuminuria with normal GFR in patients prior to initiation of HAART. The proportion of subjects with microalbuminuria in our cohort (9%; age range 2159 years) was approximately three times higher than that found in the similarly aged, non-diabetic, non-hypertensive NHANES III US population (3%) [11]. Even if the subjects receiving antihypertensives at baseline are excluded to eliminate the possibility that the cohort contains subjects truly having hypertension, diabetes or renal disease at baseline, the proportion of microalbuminurics without co-morbidity in this cohort would still be high (five out of 65, or 8%). The identification of albuminuria at baseline in this study depended on a single measurement, so misclassification is possible and may have falsely elevated the baseline prevalence of albuminuria. However, this high prevalence of microalbuminuria is corroborated by the results from a previous study [19], suggesting there truly is increased glomerular impairment in the untreated HIV population. In this study, albuminuria at baseline was associated with older age, positively correlated with HIV-1 RNA level, and negatively correlated with CD4 count. These findings are similar in direction and magnitude to those of our previous study in a different population describing dipstick-detected proteinuria in a cohort of patients at the time of HIV documentation [20], where proteinuria was also associated with older age and significantly correlated with CD4 cell count (r = 0.20, P = 0.003) and HIV-1 RNA level (r = 0.25, P = 0.005). Therefore, it seems that immune status may be associated with albuminuria in the untreated HIV population, but further research in larger cohorts is required to investigate this possibility more conclusively.
Because our primary hypothesis was that PI-based therapy would lead to systemic endothelial dysfunction, and, in turn, incipient glomerular disease, we chose to measure albuminuria, as opposed to proteinuria, as this may be a more specific measure of glomerular disease and is likely to occur earlier than overt proteinuria. However, we recognize that proteinuria is more commonly measured in clinical practice, especially when screening for HIVAN or for identifying patients with renal disease due to febrile states, which may occur frequently in the HIV population. Therefore, the results of this study may not be immediately applicable in evaluating or managing renal diseases in this special population.
In conclusion, albuminuria appears to be prevalent in the untreated HIV-infected population and may be influenced by immune status. However, we did not observe a change in ACR during the initial 64 weeks of HAART, although subjects with elevated baseline albuminuria had substantial reductions in ACR. A larger study enriched with a population likely to have more substantial albuminuria at baseline (i.e. an older African-American cohort with lower baseline CD4 cell counts) and longer duration of follow-up would perhaps find a more significant reduction in ACR with the use of HAART.
![]() |
Acknowledgments |
---|
Conflict of interest statement. S.K.G. has received speaker's fees from Gilead Sciences, Inc.; R.A.P. has consulted for Merck and Co.; G.K.R. has consulted for or received honoraria from Bristol-Myers Squibb, Agouron/Pfizer and GlaxoSmithKline; M.P.D. has received honoraria, speaker's and consultant's fees, research grants, and donated drug for research purposes from Agouron/Pfizer, GlaxoSmithKline, Gilead Sciences, Inc., Bristol-Myers Squibb and Merck and Co.
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|